7.87
-6.23 (-44.18%)
| Previous Close | 14.10 |
| Volume | 559,118 |
| Price / Sales | 1.94 |
| Price / Book | 36.54 |
| 52 Weeks Range |
| Operating Margin (TTM) | -2,921.38% |
| Diluted EPS (TTM) | -0.640 |
| Quarterly Revenue Growth (YOY) | -75.50% |
| Total Debt/Equity (MRQ) | 108.28% |
| Current Ratio (MRQ) | 1.03 |
| Operating Cash Flow (TTM) | -34.72 M |
| Levered Free Cash Flow (TTM) | -18.34 M |
| Return on Assets (TTM) | -67.62% |
| Return on Equity (TTM) | -221.66% |
AIStockmoo Score
| Value 30% | -4.2 |
| From our AI Insight report's view of expected return against risk. info | NA |
| Relative Valuation info | NA |
| Implied Growth info | NA |
| Valuation History info | NA |
| Weak profitability. Thin short-term liquidity. Negative cash flow. info | |
| Earns below its cost of capital. Returns on capital falling. info | |
| Timing 30% | -3.6 |
| From our AI technical analysis of the chart. info | NA |
| No clear trend over the past year. Far below its 52-week high. info | |
| Candle Patterns info | NA |
| Trend for Your Holding Period info | NA |
| Sentiment 20% | 0.0 |
| No recent price targets, so based on how targets have been revised. info | |
| News Mood info | NA |
| Smart Money 20% | 1.9 |
| Insider Activity info | NA |
| Institutions net +75.12% of shares in their latest 13F filings: 35 holders increased, 19 decreased (quarter to 30 Sep 2026). info | |
| Short interest +171.0% from 31 Aug to 30 Oct 2026, 7.6 days to cover (FINRA). info | |
| Market and sector conditions are poor. | |
| Market environment cautious. info | |
| Sector lagging the market. | |
| The pillars agree, so the score is strengthened. | |
| Not in score | |
| Price is low against its 52-week average. Down over 5 years. info | |
| Trend down on all three terms. Short-term momentum falling. info | |
| No clear signal from support and resistance. info | |
| Final Score | -2.43 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Cue Biopharma, Inc. | Mixed | Mixed |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| CUE | - | - | - | 36.54 |
| TRML | 1 B | - | - | 4.76 |
| CTMX | - | - | - | 1.55 |
| HURA | - | - | - | 4.84 |
| GANX | - | - | - | 4.54 |
| PRTA | - | - | - | 1.56 |
Select this tab to load the latest available analysis.
|
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.35% |
| % Held by Institutions | 19.45% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Tetragon Partners Gp Ltd | 30 Jun 2026 | 93,819 |
No data within this time range.
No data within this time range.
Institutions
Institutional ownership: 65.83%
| Positions | Holders | Shares |
|---|---|---|
| Increased | 35 | 3,280,294 |
| Decreased | 19 | 254,853 |
| New | 17 | 2,454,175 |
| Sold out | 8 | 221,057 |
SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.
Short Interest
| Settlement | Shares | Days to cover |
|---|---|---|
| 30 Oct 2026 | 862,798 | 7.6 |
| 15 Oct 2026 | 792,553 | 3.7 |
| 30 Sep 2026 | 702,198 | 1.1 |
| 15 Sep 2026 | 332,105 | 2.4 |
| 31 Aug 2026 | 318,420 | 1.8 |
| 14 Aug 2026 | 327,442 | 1.6 |
FINRA short interest via Nasdaq, reported twice a month.
| Date | Type | Details |
|---|---|---|
| 16 Nov 2026 | Yahoo Finance |
Cue Biopharma Reports Third Quarter 2026 Financial Results and Recent Business Highlights
CUE-221 Phase 2 chronic spontaneous urticaria (CSU) findings highlight differentiated clinical benefit and potential to expand the addressable patient population in CSU and food allergy CUE-401 enters clinical development with initiation of first-in-human dosing, achieving key 2026 milestone… |
| 28 Sep 2026 | Yahoo Finance |
Cue Biopharma’s CUE-221 Hits Phase II Goals, Shows Durable CSU Response
Cue Biopharma (NASDAQ:CUE) reported positive top-line results from a Phase II trial of CUE-221 in patients with moderate-to-severe chronic spontaneous urticaria, or CSU, whose disease was inadequately controlled with H1 antihistamines. The randomized, double-blind, placebo-controlled study evaluate… |
| 25 Sep 2026 | Yahoo Finance |
Cue Biopharma (CUE) Reports Hives Drug Results. Can Longer Relief Set it Apart?
Cue Biopharma, Inc. (NASDAQ:CUE) reported positive Phase 2 results for CUE-221 on September 20. The randomized, double-blind study enrolled 145 patients in China with moderate to severe chronic spontaneous urticaria, or chronic hives, inadequately controlled by H1 antihistamines. At week 12… |
| 22 Sep 2026 | Yahoo Finance |
An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill. |
| 21 Sep 2026 | Yahoo Finance |
Cue Biopharma Shares Jump 41.6% Premarket Following Phase 2 Trial Results
Cue Biopharma (NASDAQ:CUE) shares rose 41. 6% in premarket trading after the company reported positive topline results from a Phase 2 clinical trial evaluating CUE-221 in patients with moderate to severe chronic spontaneous urticaria. |
| 20 Sep 2026 | Yahoo Finance |
Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria
Results support potential for differentiated clinical impact for patients suffering from chronic hives and advancement to Phase 2b/3 registration enabling studyPrimary endpoint and the key secondary endpoint were met with high statistical significance and CUE-221 demonstrated an overall favorable… |
Recent Signals candle patterns and EMA crosses
AI Technical Analysis
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |